Sintilimab and bevacizumab after surgery for ruptured liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining two immune-based drugs (sintilimab and a bevacizumab biosimilar) after surgery can prevent liver cancer from returning in people whose tumor had ruptured. It’s for patients who have had a complete surgical removal of a ruptured hepatocellular carcinoma and are now cancer-free on imaging.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a ruptured liver tumor that was completely removed during surgery.
- You are between 18 and 75 years old.
- Your cancer is stage I or II (CNLC system) and has not spread outside the liver.
- You have good liver function (Child-Pugh A) and can care for yourself (ECOG 0-1).
- You do not have active autoimmune disease, serious infections, or uncontrolled heart or bleeding conditions.
- If you have hepatitis B, it must be well controlled with antiviral medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining an immunotherapy drug (sintilimab) with a targeted therapy (lenvatinib) after surgical removal of liver cancer can help prevent the cancer from coming back. It is for patients whose tumors show a specific blood vessel pattern called VETC.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
This trial tests a new combination treatment for liver cancer that cannot be removed with surgery. It combines targeted therapy and immunotherapy with a procedure that delivers chemotherapy directly to the liver, aiming to shrink tumors and improve outcomes.
This trial tests two drugs, sintilimab and bevacizumab, given before surgery to treat liver cancer that can be removed. It's for people with a certain stage of liver cancer who haven't had other treatments.
This trial tests a combination of three drugs (two immunotherapies and a blood vessel blocker) given before and after surgery for liver cancer. The goal is to see if this approach can shrink tumors and reduce the chance of cancer coming back.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.